The Israeli company closed a $5.6 million funding round with 5 backers, according to an SEC filing dated Sept. 5, 2014. The company offered no details on the source of the funding round or how it plans to spend its new cash.
In a separate announcement, Medigus reported that its MUSE clinical results were finally published in the journal Surgical Endoscopy. The minimally invasive MUSE device, or Medigus Ultrasonic Surgical Endostapler, showed positive 6-month results in treating patients with gastroesophageal reflux disease.
Medigus has been touting the study results for about a year, having unveiled them in 2013 and presented them at the Society of American Gastrointestinal & Endoscopic Surgeons conference earlier this year.
The MSUE device combines the company’s proprietary ScoutCam endoscopic camera and surgical stapling tools that are inserted into the esophagus through the mouth to create a fold of tissue where the esophagus meets the stomach to help prevent the backflow of stomach acids into the lower esophagus.